Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers

Drug Development and Industrial Pharmacy

Volumn 33, Issue 1, 2007, Pages 45-56

  Valizadeh, Hadi ^a,b   Zakeri Milani, Parvin ^a,b   Barzegar Jalali, Mohammad ^a,b   Mohammadi, Ghobad ^a,c   Danesh Bahreini, Mohammad Ali ^a   Adibkia, Khosro ^a   Nokhodchi, Ali ^a,d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Coevaporate; Coprecipitate; Dissolution; FT IR spectroscopy; Piroxicam; Solid dispersion; X ray diffraction

Indexed keywords

DEXTRIN; DRUG CARRIER; EUDRAGIT; MACROGOL STEARATE; MANNITOL; PIROXICAM;

ARTICLE; CONCENTRATION RESPONSE; DISPERSION; DRUG DETERMINATION; DRUG FORMULATION; DRUG MIXTURE; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; HYDROPHILICITY; INFRARED SPECTROSCOPY; SIMULATION; STOMACH JUICE; X RAY DIFFRACTION;

ACRYLATES; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; PIROXICAM; POLYMERS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 33845945486     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040600814965     Document Type: Article

References (31)

1. Abd El Fattah, S., Salib, N. N., & El Massik, M. (1984). A new approach for controlling the release rate of pheniramine aminosalicylate via solid dispersion in different types of Eudragit. Drug Development and Industrial Pharmacy, 10(4), 649-666.
2. Amidon, G. L., Lennernas, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12, 413-420.
3. Aulton, M. E. (1994). Pharmaceutics: The Science of dosage form and design; Churchill Livingstone: London.
4. Chiou, W. L., & Riegelman, S. (1971). Pharmaceutical applications of solid dispersion systems. Journal of pharmaceutical sciences, 60(9), 1281-1302.
5. Craig, D. Q. M. (2002). The mechanisms of drug release from solid dispersions in water-soluble polymers. International Journal of Pharmaceutics, 231(2), 131-144.
6. Ediger, M. D., Angell, C. A., & Nagel, S. R. (1996). Supercooled liquids and glasses. J. Phys. Chem., 100, 13200-13212.
7. Ford, J. L. (1986). The current status of solid dispersions. Pharmaceutica Acta Helvetiae, 61(3), 69-88.
8. Hancock, B. C., & Parks, M. (2000). What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res., 17, 397-404.
9. Hancock, B. C., & Zografi, G. (1994). The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm. Res., 11, 471-477.
10. Hancock, B. C., & Zografi, G. (1997). Characteristics and Significance of the Amorphous State in Pharmaceutical Systems. Journal of Pharmaceutical Sciences, 86(1), 1-12.
11. Higuchi, T., & Connors, K. A. (1965). Phase-solubility techniques. Adv. Anal. Chem. Instr., 4, 117-212.
12. Khouzagaz, K., & Clas, S. D. (2000). Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. J. Pharm. Sci., 89, 1325-1334.
13. Kuhnert-Brandstätter, M., & Völlenklee, R. (1985). Thermoanalytische und IR- pectroskopische Untersuchungen an Polymorphen Arzneistoffen: Acemetacin, Piroxicam, Propranolohydrochlorid and Urapidil. Frasenius Z. Anal. Chem., 322, 164-169.
14. Leuner, C., & Dressman, J. (2000). Improving drug solubility for oral delivery using solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 47-60.
15. Löbenberg, R., Amidon, G. L. (2000) Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 3-12.
16. Martin, A. (1993). Physical Pharmacy; Lea & Febiger: Philadelphia, PA.
17. Matsumoto, T., & Zografi, G. (1999). Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization. Pharmaceutical Research, 16(11), 1722-1728.
18. Mihalic, M., Hofman, H., Kajfez, R. F., Kuftinec, J., Blazevic, N., & Zimic, M. (1982). Physico-chemical and analytical characteristics of piroxicam. Acta Pharm. Jug., 32, 13-20.
19. Mihalic, M., Hofman, H., Kuftinec, J., Kajfez, R. F., Krile, B., Caplar, V., & Blazevic, N. (1986). Piroxicam. In: Analytical profiles of drug substances; Florey, K., ed., Academic press: London, pp. 509-531.
20. Nagarsenker, M., & Garad, S. (1998). Physical characterization and optimization of dissolution parameters of prochlorper-azine maleate coevaporates. Int. J. Pharm., 160, 251-255.
21. Nikolakakis, I., Kachrimanis, K., & Malamataris, S. (2000). Relations between crystallisation conditions and micromeritic properties of ibuprofen. Int. J. Pharm., 201, 79-88.
22. Ntawukulilyayo, J. D., Bouckaert, S., & Remon, J. P. (1993). Enhancement of dissolution rate of nifedipine using sucrose ester coprecipitates. Int. J. Pharm., 93, 209-214.
23. Okimoto, K., Miyake, M., Ibiki, R., Yasumura, M., Ohnishi, N., & Nakai, T. (1997). Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypro-pylmethylcellulose. Int. J. Pharm., 159, 85-93.
24. Proudfoot, S. G. (1988). Introduction to biopharmaceutics. In: Pharmaceutics: The Science of Dosage Form Design., Aulton, M. E., ed., Churchill Livingstone: London, p. 131.
25. Sekikawa, H., Nakano, M., & Arita, T. (1979). Dissolution mechanisms of drug-polyvinylpyrrolidone coprecipitates in aqueous solution. Chemical and Pharmaceutical Bulletin, 27(5), 1223-1230.
26. Shin, S. C., & Chiou, C. W. (1997). Physicochemical characterizations of piroxicam_/poloxamer solid dispersion. Pharm. Dev. Technol., 2, 403-407.
27. Simonelli, A. P., Mehta, S. C., & Higuchi, W. I. (1976). Dissolution rates of high energy sulfathiazole-povidone coprecipitate II: characterization of form of drug controlling its dissolution rates via solubility studies. J. Pharm. Sci., 65, 355-361.
28. Tantishaiyakul, V., & Kaewnopparat, N. (1999). Ingkatawornwong, S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int. J. Pharm., 181, 143-151.
29. Valizadeh, H., Nokhodchi, A., Qarakhani, N., Zakeri-Milani, P., Azarmi, S., Hassanzadeh, D., & Löbenberg, R. (2004). Physicochemical Characterization of Solid Dispersions of Indomethacin with PEG 6000, Myrj 52, Lactose, Sorbitol, Dextrin, and Eudragit® E100. Drug Development and Industrial Pharmacy, 30(3), 303-317.
30. Vrecer, F., Vrbrinc, M., & Meden, A. (2003). Characterization of piroxicam crystal modifications. Int. j. Pharm., 256, 3-15.
31. Yoshioka, M., Hancock, B. C., & Zografi, G. (1995). Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J. Pharm. Sci., 84, 983-986.